PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10190792-9	1999	The retinoids, as a class, can inhibit the growth of resistant cell lines that overexpress bcl-2, and the combination of interferon (IFN) and cis-retinoic acid (CRA) demonstrated increased antitumor activity.	Isotretinoin	161-164	interferon alpha 1	Homo sapiens	121-131	
12209689-7	2002	CONCLUSIONS: The current data suggest that combined outpatient sc IFN-alpha and sc IL-2, according to the Atzpodien regimen, achieves long-term survival benefits in a subset of patients with metastatic renal cell carcinoma, both with and without 13-cis-retinoic acid and/or 5-fluorouracil.	Isotretinoin	246-266	interferon alpha 1	Homo sapiens	66-75	
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	57-77	interferon alpha 1	Homo sapiens	120-123	
11943887-2	2002	Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week.	Isotretinoin	79-82	interferon alpha 1	Homo sapiens	120-123	
10561278-8	1999	Pharmacokinetic studies demonstrated that CRA/IFNalpha caused a 33% decrease in TAX clearance and a 23% decrease in the area under the concentration-time curve values of the TAX metabolite 6-alfa-hydroxytaxol (6-HT).	Isotretinoin	42-45	interferon alpha 1	Homo sapiens	46-54	
10851460-2	1997	More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients.	Isotretinoin	101-121	interferon alpha 1	Homo sapiens	151-160	
10851460-2	1997	More recently, clinical and pre-clinical results provide evidence for an antiproliferative effect of 13-cis-retinoic acid (13cRA) in interferon-alpha (IFN-alpha) treated renal cell carcinoma patients.	Isotretinoin	123-128	interferon alpha 1	Homo sapiens	151-160	
10851460-3	1997	The manner in which 13cRA augments antitumor effects and modulates biologic and clinical responses of renal cell carcinoma to IFN-alpha remains elusive.	Isotretinoin	20-25	interferon alpha 1	Homo sapiens	126-135	
10851460-4	1997	In the present study, we report induction of apoptosis and objective tumor regression in response to 13cRA in advanced renal cell carcinoma patients refractory to IFN-alpha.	Isotretinoin	101-106	interferon alpha 1	Homo sapiens	163-172